Cytogen completes CytoRad acquisition
Monoclonal antibody developer Cytogen put the finishing touches on its acquisition of sistercompany CytoRad last month. CytoRad will now be a wholly ownedsubsidiary of Cytogen, the Princeton, NJ, company said. CytoRad was initially formed as a separate
Monoclonal antibody developer Cytogen put the finishing touches on its acquisition of sistercompany CytoRad last month. CytoRad will now be a wholly ownedsubsidiary of Cytogen, the Princeton, NJ, company said.
CytoRad was initially formed as a separate company to pay forR&D at Cytogen, but the two firms began feuding last yearand CytoRad cut off funding (SCAN 6/29/94 and 4/20/94). The disputecontributed to a shortfall of millions of dollars in Cytogen'srevenues last year (SCAN 3/1/95).
The acquisition will resolve the differences between the companiesand will assure Cytogen of a stable source of R&D funds. Cytogenbought CytoRad by trading each share of CytoRad stock for 1.5shares of Cytogen common stock, a warrant expiring in 1997 toacquire one share of Cytogen common stock for $8 a share, anda contingent value right (CVR) to receive additional shares ofCytogen stock if certain conditions are met.
Study Shows No Impact of Hormone Therapy on PET/CT with 18F-Piflufolastat in PCa Imaging
May 7th 2025For patients with recurrent or metastatic prostate cancer, new research findings showed no significant difference in the sensitivity of 18F-piflufolastat PET/CT between patients on concurrent hormone therapy and those without hormone therapy.
